(Q44299542)

1 December 2017

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial (English)

1 reference

1 December 2017

0 references

1 reference

3

1 reference

1 December 2017

12

1 reference

1 December 2017

31

1 reference

1 December 2017

Trevor F Cox

5

0 references

Eithne Costello

object named as

Eithne Costello

10

0 references

Bengt Glimelius

19

object named as

Bengt Glimelius

1 reference

1 December 2017

27

Julia Mayerle

1 reference

1 December 2017

33

Markus W Büchler

1 reference

1 December 2017

32

Claudio Bassi

1 reference

1 December 2017

1

William Greenhalf

1 reference

1 December 2017

2

Paula Ghaneh

1 reference

1 December 2017

Charlotte L Rawcliffe

30

object named as

Charlotte L Rawcliffe

1 reference

1 December 2017

26

Christopher M Halloran

1 reference

1 December 2017

25

Alan Anthoney

1 reference

1 December 2017

Daniel H Palmer

4

1 reference

1 December 2017

Richard F Lamb

6

1 reference

1 December 2017

Elizabeth Garner

7

1 reference

1 December 2017

Fiona Campbell

8

1 reference

1 December 2017

John R Mackey

9

1 reference

1 December 2017

Malcolm J Moore

11

1 reference

1 December 2017

Alexander C McDonald

13

1 reference

1 December 2017

Ross Carter

14

1 reference

1 December 2017

Niall C Tebbutt

15

1 reference

1 December 2017

David Goldstein

16

1 reference

1 December 2017

Jennifer Shannon

17

1 reference

1 December 2017

Christos Dervenis

18

1 reference

1 December 2017

Mark Deakin

20

1 reference

1 December 2017

Richard M Charnley

21

1 reference

1 December 2017

François Lacaine

22

1 reference

1 December 2017

Andrew G Scarfe

23

1 reference

1 December 2017

Mark R Middleton

24

1 reference

1 December 2017

Attila Oláh

28

1 reference

1 December 2017

Richard Jackson

29

1 reference

1 December 2017

European Study Group for Pancreatic Cancer

34

1 reference

1 December 2017

language of work or name

English

0 references

publication date

3 December 2013

1 reference

Journal of the National Cancer Institute

1 December 2017

1 reference

1 December 2017

106

1 reference

1 December 2017

1

1 reference

1 December 2017

djt347

1 reference

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

1 December 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

Adjuvant chemoradiation for pancreatic cancer: few good data, much debate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

New biomarkers and targets in pancreatic cancer and their application to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

Reporting recommendations for tumor marker prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. Ent2 exhibits a low affinity for guanosine and cytidine but a high affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT347

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJT347

1 reference

1 December 2017

1 reference